^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR7390

    i
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    MEK1 inhibitor, MEK2 inhibitor
    Related drugs:
    Apply
    Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN) (NCT04355858)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    07/26/2022
    Initiation :
    05/01/2020
    Primary completion :
    05/01/2023
    Completion :
    04/01/2025
    HER-2 • ER • PGR
    |
    ER positive • HR positive • HER-2 negative • PGR positive
    |
    Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR-2554 • SHR7390 • Airui'en (rezvilutamide)